STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLDX
  4. [Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

CLDX insider awarded 100,000 stock options; 25% vests 11/10/2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Celldex Therapeutics (CLDX) reported a Form 4 for its SVP & Chief Commercial Officer, noting the grant of 100,000 stock options on 11/10/2025 under the company’s 2021 Omnibus Equity Incentive Plan at an exercise price of $22.67 per share. The options expire on 11/10/2035.

The filing states 25% of the award vests on 11/10/2026, with the remainder vesting in equal quarterly installments over the next 12 quarters. Following the grant, 100,000 derivative securities are listed as beneficially owned in direct form.

Positive

  • None.

Negative

  • None.

Insights

Routine insider option grant with time-based vesting.

This Form 4 records an option award of 100,000 shares at an exercise price of $22.67, granted on 11/10/2025 and expiring on 11/10/2035. The award was made under the company’s 2021 Omnibus Equity Incentive Plan, a standard equity compensation vehicle.

Vesting is time-based: 25% on 11/10/2026, then equal quarterly vesting over 12 quarters. This structure aligns incentives over multiple years and does not itself signal a change in business outlook.

As disclosed, 100,000 derivative securities are beneficially owned directly after the transaction. The filing reflects compensation administration; actual impact depends on future vesting and exercise decisions.

Insider Lawver Teri L
Role SVP & Chief Commercial Officer
Type Security Shares Price Value
Grant/Award ISO (right to buy) 100,000 $0.00 $0.00
Holdings After Transaction: ISO (right to buy) — 100,000 shares (Direct)
Footnotes (2)
  1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
  2. F2. 25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

FAQ

What did Celldex (CLDX) disclose in this Form 4?
A grant of 100,000 stock options to the SVP & Chief Commercial Officer at an exercise price of $22.67 on 11/10/2025.

What is the vesting schedule for the CLDX option grant?
25% vests on 11/10/2026, and the remainder vests quarterly in equal amounts over the next 12 quarters.

When do the Celldex options expire?
The options expire on 11/10/2035.

How many derivative securities are beneficially owned after the transaction?
100,000 derivative securities are listed as beneficially owned in direct form.

Under which plan were the CLDX options granted?
The award was granted under Celldex’s 2021 Omnibus Equity Incentive Plan.

Who received the option grant at CLDX?
The company’s SVP & Chief Commercial Officer received the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lawver Teri L
(Last) (First) (Middle)
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
(Street)
HAMPTON NJ 08827
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
ISO (right to buy)(1) $22.67 11/10/2025(1) A 100,000 11/10/2026(2) 11/10/2035 Common Stock 100,000 $0 100,000 D
Explanation of Responses:
1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. 25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Sam Martin, attorney-in-fact for Teri Lawver 11/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR